Topic: age-related macular degeneration
Regeneron CEO Len Schleifer netted $26.5 million in pay in 2018, keeping him among the top three highest-earning CEOs in the industry.
Novartis is “actively evaluating” digital therapeutics for potential deals, according to the exec heading up its post-Alcon eye business.
To focus as what CEO Vas Narasimhan calls “a medicines company,” Novartis made a series of M&A decisions in 2018.
Roche grew sales by 7% in 2018, even as biosimilar rivals unleashed damage in Europe. But 2019 will be the moment of truth for the Swiss drugmaker. U.S. copycats to its trio of cancer megablockbusters—Herceptin, Rituxan and Avastin—are expected to arrive.
Bayer’s Xarelto and Eylea are still the top performers within the company’s pharma business. But both drugs are looking at a bumpy road ahead.
Investors had been worried that growth for Regeneron’s Eylea was slowing down, but Monday the company batted away those fears.
The eye drug star has nabbed an FDA nod as a 12-week formulation in wet AMD and is expected to get into diabetic retinopathy next May.
The latest data from trials of Novartis's RTH258 to treat macular degeneration suggest it could be a threat to Regeneron's blockbuster Eylea.
Regeneron’s flagship med Eylea fell short of sales expectations in Q1, raising questions as Praluent idles and potential big-earner Dupixent makes its debut.